<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369082</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT CIT-08</org_study_id>
    <nct_id>NCT01369082</nct_id>
  </id_info>
  <brief_title>Extended Follow-Up After Islet Transplantation in T1D</brief_title>
  <official_title>Extended Follow-Up After Islet Transplantation in Type 1 Diabetes (CIT-08)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Islet Transplantation Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide patients who have received at least one islet&#xD;
      transplant as a previous participant in a Clinical Islet Transplantation Consortium (CIT)&#xD;
      clinical trial with maintenance immunosuppressive medications and to collect information&#xD;
      about the safety of the medications and islet function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After islet-cell transplantation in the CIT studies*, each subject receives maintenance&#xD;
      immunosuppressive medications.&#xD;
&#xD;
      The purpose of this protocol is to collect additional follow-up for safety and efficacy from&#xD;
      CIT subjects with graft function after their completion in their CIT parent study. It is&#xD;
      expected that most subjects will retain measurable islet function and, in the islet-alone&#xD;
      studies, continue to receive immunosuppressive medications at the time of completing their&#xD;
      CIT parent study.&#xD;
&#xD;
      *CIT parent studies: CIT02 (NCT00464555), CIT03 (NCT00434850), CIT04 (NCT00468403), CIT05&#xD;
      (NCT00468442), CIT06 (NCT00468117), and CIT07 (NCT00434811)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of sustained islet allograft function</measure>
    <time_frame>Month 36,48,60,72,84,96,108,120,132 and 144 status post last islet transplant</time_frame>
    <description>A C-peptide &gt;/= 0.3 ng/mL at 0, 60, or 90 minutes after a Mixed-Meal Tolerance Test (MMTT) will be considered evidence of insulin production by transplanted islets</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine and calculated eGFR at each annual study visit</measure>
    <time_frame>Month 36,48,60,72,84,96,108,120,132 and 144 status post last islet transplant</time_frame>
    <description>Measured as part of each annual follow-up evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs) during the 12-month period preceding each annual study visit</measure>
    <time_frame>Month 36,48,60,72,84,96,108,120,132 and 144 status post last islet transplant</time_frame>
    <description>Insulin usage will be estimated from the one-week self report values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin requirements during a one-week period preceding each annual study visit</measure>
    <time_frame>Month 36,48,60,72,84,96,108,120,132 and 144 status post last islet transplant</time_frame>
    <description>Insulin usage will be estimated from the one-week self report values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hypoglycemic events during the 12-month period preceding each annual study visit</measure>
    <time_frame>36 months, 48 months, 60 months, 72 months, 84 months, 96 months, 108 months, 120 months, 132 months and 144 months</time_frame>
    <description>Numbers of severe hypoglycemic events will be estimated from the self report values obtained at each follow-up visit. Defined as an event with one of the following symptoms: memory loss; confusion; uncontrollable behavior; irrational behavior; unusual difficulty in awakening; suspected seizure; seizure; loss of consciousness; or visual symptoms, in which the subject was unable to treat him/herself and which was associated with either a blood glucose level &lt;54 mg/dL (3.0 mmol/L) or prompt recovery after oral carbohydrate, IV glucose, or glucagon administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c levels at each annual study visit</measure>
    <time_frame>Month 36,48,60,72,84,96,108,120,132 and 144 status post last islet transplant</time_frame>
    <description>Glycosylated hemoglobin test determination during each follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause mortality</measure>
    <time_frame>By month 144 status post last islet transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor-specific alloantibodies</measure>
    <time_frame>By month 144 status post last islet transplant</time_frame>
    <description>Subjects with confirmed graft failure will continue with annual study visits; however, metabolic assessments should not be completed. Subjects who were enrolled in islet-alone parent studies and who experience graft failure and subsequently stop immunosuppression will have alloantibody assessed 3 months after their last dose of immunosuppression.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">75</enrollment>
  <condition>Type 1 Diabetes (T1D)</condition>
  <condition>Islet Transplantation</condition>
  <arm_group>
    <arm_group_label>CIT Islet Transplantation Recipients</arm_group_label>
    <description>Subjects who received an islet-cell transplant for Type 1 Diabetes (T1D) while enrolled in one of the Clinical Islet Transplantation (CIT) parent studies and continue to have islet graft function. All subjects will continue immunosuppressive medications under CIT08. Detailed follow-up evaluations including but not limited to islet function will occur on an annual basis.&#xD;
The immunosuppressive medications (e.g., tacrolimus, sirolimus, cyclosporine, mycophenolate mofetil [MMF], mycophenolic sodium) in this study are obtained by prescription unless provided by the study through the drug distributor. Generic brands are allowed, when available. Antibacterial, antifungal, and antiviral prophylaxis, insulin therapy, and other standard therapies will be provided per site-specific practices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance Immunosuppressive Treatment</intervention_name>
    <description>All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.</description>
    <arm_group_label>CIT Islet Transplantation Recipients</arm_group_label>
    <other_name>tacrolimus</other_name>
    <other_name>Prograf®</other_name>
    <other_name>FK506</other_name>
    <other_name>sirolimus</other_name>
    <other_name>rapamycin</other_name>
    <other_name>Rapamune®</other_name>
    <other_name>cyclosporine</other_name>
    <other_name>Neoral®</other_name>
    <other_name>mycophenolate mofetil (MMF)</other_name>
    <other_name>CellCept®</other_name>
    <other_name>mycophenolic sodium</other_name>
    <other_name>Myfortic®</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants are given the option to provide consent for:&#xD;
&#xD;
        1. the collection and storage of blood samples for future research studies&#xD;
&#xD;
        2. the collection and storage of blood samples for future genetic (i.e., DNA) testing.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort from Clinical Islet Transplantation (CIT) parent studies (refer to inclusion&#xD;
        criteria) who continue:&#xD;
&#xD;
          -  to have islet graft function and&#xD;
&#xD;
          -  are on prescribed immunosuppression medications to prevent rejection of their&#xD;
             transplant.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received an islet transplant during participation in the following&#xD;
             Clinical Islet Transplantation (CIT) parent studies: CIT02 (NCT00464555), CIT03&#xD;
             (NCT00434850), CIT04 (NCT00468403), CIT05 (NCT00468442), CIT06 (NCT00468117), and&#xD;
             CIT07 (NCT00434811)&#xD;
&#xD;
          -  A functioning pancreatic islet graft (e.g., absence of graft failure as defined in&#xD;
             parent study) requiring immunosuppression&#xD;
&#xD;
          -  Willingness of participants to continue to use an approved method of contraception&#xD;
             during and 4 months after study participation&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
          -  Resident of the United States of America&#xD;
&#xD;
          -  Documentation of the existence or lack of health insurance coverage and whether&#xD;
             immunosuppressants are covered.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For female subjects-Positive pregnancy test, presently breast-feeding, or&#xD;
             unwillingness to use effective contraceptive measures for the duration of the study&#xD;
             and 4 months after discontinuation&#xD;
&#xD;
          -  For male subjects-Intent to procreate during the duration of the study or within 4&#xD;
             months after discontinuation or unwillingness to use effective measures of&#xD;
             contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with&#xD;
             spermicide are acceptable contraceptive methods; condoms used alone are not&#xD;
             acceptable.&#xD;
&#xD;
          -  Received an islet transplant in a non-CIT research study&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigator, will interfere with&#xD;
             safe participation in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Hering, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Naji, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camillo Ricordi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Posselt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole Turgeon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xunrong Luo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02493</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT)</description>
  </link>
  <link>
    <url>http://www.niddk.nih.gov/Pages/default.aspx</url>
    <description>National Institute of Diabetes and Digestive and Kidney Diseases</description>
  </link>
  <link>
    <url>http://www.citisletstudy.org/</url>
    <description>Clinical Islet Transplantation Consortium</description>
  </link>
  <reference>
    <citation>Rickels MR, Liu C, Shlansky-Goldberg RD, Soleimanpour SA, Vivek K, Kamoun M, Min Z, Markmann E, Palangian M, Dalton-Bakes C, Fuller C, Chiou AJ, Barker CF, Luning Prak ET, Naji A. Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes. 2013 Aug;62(8):2890-7. doi: 10.2337/db12-1802. Epub 2013 Apr 29.</citation>
    <PMID>23630300</PMID>
  </reference>
  <reference>
    <citation>Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28;355(13):1318-30.</citation>
    <PMID>17005949</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>June 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>islet allograft function</keyword>
  <keyword>c-peptide production</keyword>
  <keyword>maintenance immunosuppressive medications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

